213 related articles for article (PubMed ID: 36427344)
1. Annual costs among patients with major depressive disorder and the impact of key clinical events.
Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
[No Abstract] [Full Text] [Related]
2. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.
Hidalgo-Mazzei D; Berk M; Cipriani A; Cleare AJ; Florio AD; Dietch D; Geddes JR; Goodwin GM; Grunze H; Hayes JF; Jones I; Kasper S; Macritchie K; McAllister-Williams RH; Morriss R; Nayrouz S; Pappa S; Soares JC; Smith DJ; Suppes T; Talbot P; Vieta E; Watson S; Yatham LN; Young AH; Stokes PRA
Br J Psychiatry; 2019 Jan; 214(1):27-35. PubMed ID: 30520709
[TBL] [Abstract][Full Text] [Related]
3. Ketamine: stimulating antidepressant treatment?
Malhi GS; Byrow Y; Cassidy F; Cipriani A; Demyttenaere K; Frye MA; Gitlin M; Kennedy SH; Ketter TA; Lam RW; McShane R; Mitchell AJ; Ostacher MJ; Rizvi SJ; Thase ME; Tohen M
BJPsych Open; 2016 May; 2(3):e5-e9. PubMed ID: 27703782
[TBL] [Abstract][Full Text] [Related]
4. Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective.
Schein J; Adler LA; Childress A; Gagnon-Sanschagrin P; Davidson M; Kinkead F; Cloutier M; Guérin A; Lefebvre P
J Manag Care Spec Pharm; 2022 Feb; 28(2):168-179. PubMed ID: 34806909
[No Abstract] [Full Text] [Related]
5. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
6. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
[TBL] [Abstract][Full Text] [Related]
7. Place of care and costs associated with acute episodes and remission in schizophrenia.
McIntyre RS; Higa S; Doan QV; Amari DT; Mercer D; Gillard P; Harrington A
J Manag Care Spec Pharm; 2023 May; 29(5):499-508. PubMed ID: 37121252
[No Abstract] [Full Text] [Related]
8. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
Fendrick AM; Brixner D; Rubin DT; Mease P; Liu H; Davis M; Mittal M
J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
[No Abstract] [Full Text] [Related]
9. The Emerging Role of Pimavanserin in the Management of Parkinson's Disease Psychosis.
Hermanowicz N; Alva G; Pagan F; Espay AJ; Patel A; Madrid KC; Kremens D; Kenney J; Arquette S; Tereso G; Lopes M; Farnum C
J Manag Care Spec Pharm; 2017 Jun; 23(6-b Suppl):S2-S8. PubMed ID: 28636480
[TBL] [Abstract][Full Text] [Related]
10. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
J Urol; 2023 Jul; 210(1):224-226. PubMed ID: 37119051
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
[No Abstract] [Full Text] [Related]
12. Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine.
Buse DC; Yugrakh MS; Lee LK; Bell J; Cohen JM; Lipton RB
J Manag Care Spec Pharm; 2020 Oct; 26(10):1334-1343. PubMed ID: 32678721
[TBL] [Abstract][Full Text] [Related]
13. Effect of Headache-Free Days on Disability, Productivity, Quality of Life, and Costs Among Individuals with Migraine.
Lipton RB; Lee L; Saikali NP; Bell J; Cohen JM
J Manag Care Spec Pharm; 2020 Oct; 26(10):1344-1352. PubMed ID: 32678720
[TBL] [Abstract][Full Text] [Related]
14. CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.
Newsome SD; Aliotta PJ; Bainbridge J; Bennett SE; Cutter G; Fenton K; Lublin F; Northrop D; Rintell D; Walker BD; Weigel M; Zackowski K; Jones DE
Int J MS Care; 2016; 18(6):314-323. PubMed ID: 27999526
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
[TBL] [Abstract][Full Text] [Related]
16. Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER).
Ambrosini A; Estemalik E; Pascual J; Rettiganti M; Stroud C; Day K; Ford J
J Manag Care Spec Pharm; 2022 Jun; 28(6):645-656. PubMed ID: 35451858
[No Abstract] [Full Text] [Related]
17. Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial.
Holt RIG; Gossage-Worrall R; Hind D; Bradburn MJ; McCrone P; Morris T; Edwardson C; Barnard K; Carey ME; Davies MJ; Dickens CM; Doherty Y; Etherington A; French P; Gaughran F; Greenwood KE; Kalidindi S; Khunti K; Laugharne R; Pendlebury J; Rathod S; Saxon D; Shiers D; Siddiqi N; Swaby EA; Waller G; Wright S
Br J Psychiatry; 2019 Feb; 214(2):63-73. PubMed ID: 30251622
[TBL] [Abstract][Full Text] [Related]
18. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions.
Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
J Manag Care Spec Pharm; 2020 Aug; 26(8):996-1007. PubMed ID: 32552362
[TBL] [Abstract][Full Text] [Related]
19. Associations between childhood maltreatment and inflammatory markers.
Palmos AB; Watson S; Hughes T; Finkelmeyer A; McAllister-Williams RH; Ferrier N; Anderson IM; Nair R; Young AH; Strawbridge R; Cleare AJ; Chung R; Frissa S; Goodwin L; Hotopf M; Hatch SL; Wang H; Collier DA; Thuret S; Breen G; Powell TR
BJPsych Open; 2019 Jan; 5(1):e3. PubMed ID: 30762500
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.
Xing S; Batt K; Kuharic M; Bullano M; Caicedo J; Chakladar S; Markan R; Farahbakhshian S
J Manag Care Spec Pharm; 2023 Jun; 29(6):626-634. PubMed ID: 37276033
[No Abstract] [Full Text] [Related]
[Next] [New Search]
